$840,000.00 in Sales Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter
Equities research analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to post $840,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Syros Pharmaceuticals’ earnings. The highest sales estimate is $1.75 million and the lowest is $380,000.00. The company is expected to announce its next earnings results on Wednesday, November 14th.
On average, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.91 million for the current year, with estimates ranging from $370,000.00 to $4.25 million. For the next fiscal year, analysts forecast that the firm will report sales of $2.92 million per share, with estimates ranging from $600,000.00 to $7.08 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Friday, August 10th. The company reported ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07. The business had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.33 million.
Syros Pharmaceuticals traded up $0.26, hitting $12.22, during trading hours on Wednesday, MarketBeat Ratings reports. 67,963 shares of the stock were exchanged, compared to its average volume of 116,961. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $23.61. The company has a market cap of $388.04 million, a price-to-earnings ratio of -5.74 and a beta of -2.44.
Several hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP lifted its stake in shares of Syros Pharmaceuticals by 80.3% in the 4th quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock valued at $206,000 after purchasing an additional 9,439 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Syros Pharmaceuticals by 299.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after purchasing an additional 9,691 shares during the period. Rhumbline Advisers lifted its stake in shares of Syros Pharmaceuticals by 87.6% in the 2nd quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock valued at $229,000 after purchasing an additional 10,494 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter valued at $105,000. Finally, Citadel Advisors LLC acquired a new position in shares of Syros Pharmaceuticals in the 2nd quarter valued at $186,000. 57.07% of the stock is currently owned by institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Featured Story: Should I invest in “strong buy” stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.